


COVID Vaccine Planning Update

Tim Davis, PharmD Eastern Region Pharmacist North Carolina Public Health Preparedness and Response

SHPR Quarterly Meeting – Aug. 19, 2020







R&D + Preclinical Trials Vaccine Candidate/s Identified Phase II Clinical Trials Manufacturing Phase II Clinical Trials Distribution

https://www.businessinsider.com/coronavirus-vaccine-timeline-trump-operation-warp-speed-timeline-2020-8 - accessed 8/18/2020

FDA Published Standards for COVID Vaccine Trials

- June 2020 FDA Published "Guidance for Industry"
- Key Principles
 - Phase 3 trials should be Randomized, Placebo-controlled Efficacy Trials
 - -~30,000 volunteers
 - Study population: Diverse, \geq 18 yo, with subsets in high risk groups
 - Primary Endpoint: Prevention of symptomatic COVID-19 disease
 - Primary efficacy endpoint at least 50%
 - Common Data Safety Monitoring Board (DSMB) across all trials (NIAID)



Front Runner Vaccine Candidates

Company	Candidate	Platform	Current Phase	OWS Funding	Dose commitment
AstraZeneca/Oxford Univ.	AZD1222	Viral vector	3	\$1.2B	300M
Moderna	mRNA-1723	mRNA	3	\$1.5B	100M
Johnson & Johnson (Janssen)	Ad26 SARS-CoV-2	Viral vector	1/2	\$1.5B	100M
Novavax	NVX-CoV2373	Protein subunit	1/2	\$1.6B	100M
Pfizer/BioNTech	BNT162	mRNA	2/3	\$1.95B	100M
GlaxoSmithKline/Sanofi		Protein subunit	Pre-clinical	\$2.1B	100M

Interested in participating in a COVID Vaccine Trial?

<u>COVID-19 Prevention Network – Volunteer Registry</u>


COVID-19 Vaccine Planning Assumptions

- Limited COVID-19 doses will be available in fall of 2020
 - October is target for CDC to have plans ready
- Initial populations recommended for COVID-19 vaccination will likely be:
 - Healthcare Workers
 - Those that maintain essential functions of society
 - Residents and staff at LTC facilities
- Initial doses may be authorized under EUA from FDA
- Likely 2 doses will be needed
 - >21 or >28 days apart
 - Both doses will need to be same product

COVID-19 Vaccine Planning Assumptions cont'd

- All vaccine candidates require some level of cold chain mgmt.
- Some candidates <u>currently</u> require ultra low cold chain (ULC)
 ULC means < -70°C
- Recommendation for target groups subject to change based on vaccine supply and characteristics
- Planning should include high demand and low demand scenarios
- Routine immunization programs must continue





Current Federal Level Planning Activities:

- Building model plans, by working with select state/local jurisdictions that will be shared
- Collaborating with various agencies to determine priority groups
- Establishing MOAs with nationwide providers (large chain drug stores and federal providers)

Current State Level Vaccine Planning Activities:

- Forming COVID vaccine planning team
- Reviewing existing mass vaccination plans
- Reviewing H1N1 lessons learned
- Assessing current status of
 - Vaccine storage capabilities
 - Pharmacy distribution
 - Immunization registry
 - Onboarding process for new users

Current suggestions for local planning activities:

- Form local COVID vaccine planning team
- Assess existing mass vaccination plans
- Review H1N1 lessons learned
- Think about high-risk groups in your community and ways to reach them
- Stay current with the latest information
 - Weekly LHD call

A few notes about Seasonal Flu:

- Increase Flu vaccine coverage among adults
 - Target those at high risk for complications
 - Reduce strain on healthcare system
- For the 2020-2021 Flu Season ONLY
 - NCIP providers can use 2-way borrowing policy for flu vaccine
 - Amount of flu vaccine that can be borrowed between stocks is <u>not</u> limited to a certain amount
- LHD's should expect communication from State IB soon

Vaccine Planning Resources (Pre-COVID)

<u>2019-2024 Public Health Emergency Preparedness (PHEP) Notice</u> <u>of Funding Opportunity – Supplemental Guidance and Resources</u>

Domain 4: Key Components of Pandemic Influenza Operational Readiness

CDC - March 2019

Interim Updated Planning Guidance on Allocating and Targeting Pandemic Influenza Vaccine during an Influenza Pandemic

CDC – December 2018

Additional Sources of Information

Advisory Committee on Immunization Practices (ACIP)

FDA COVID-19 Website

Clinicaltrials.gov

CDC COVID-19 Website

North Carolina COVID-19 Dashboard

WHO – Draft Landscape of COVID-19 Candidate Vaccines

Questions?

Tim Davis, PharmD Eastern Region Pharmacist, NC PHP&R <u>Tim.Davis@dhhs.nc.gov</u> 252-822-2477